Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034)

Blood

Volumn 113, Issue 19, 2009, Pages 4819-4820

  Prince, H Miles ^a   Hönemann, Dirk ^a   Spencer, Andrew ^a   Rizzieri, David A ^a   Stadtmauer, Edward A ^a   Roberts, Andrew W ^a   Bahlis, Nizar ^a   Tricot, Guido ^a   Bell, Bill ^a   DeMarini, Douglas J ^a   Suttle, A Benjamin ^a   Baker, Katherine L ^a   Pandite, Lini N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; VASCULOTROPIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; LETTER; MULTIPLE MYELOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; ADULT; AGED; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SAFETY; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRIMIDINES; SAFETY; SALVAGE THERAPY; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66549095182     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-207209     Document Type: Letter

References (10)

1. Podar K, Catley LP, Tai YT, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004;103:3474-3479. (Pubitemid 38525680)
2. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors [abstract]. J Clin Oncol. 2005;23(suppl):195s. Abstract 3012.
3. Sleijfer S, Papai Z, Le Cesne A, et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043 [abstract]. J Clin Oncol. 2007;25(suppl):552s. Abstract 10031.
4. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: initial results of a phase II study [abstract]. J Clin Oncol. 2007;25(suppl):289s.
5. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract]. J Clin Oncol. 2008;26(suppl):261s. Abstract 5046.
6. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012-2021. (Pubitemid 47052491)
7. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther. 2003;307:476-480.
8. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol. 2006;142:1477-1479. (Pubitemid 44790642)
9. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND. 145. Invest New Drugs. 2006;24:529-535.
10. Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004;10:88-95. (Pubitemid 38114166)